Clinical Trial SignalWhat changed. Why it matters. Evidence. Caveats.
Briefs are AI-assisted, source-anchored, never invented. Every fact links to a primary record. Every conclusion carries its caveat.
Generate live AI briefs
Example brief
What changed. ClinicalTrials.gov registry record updated to move primary completion date from 2026-12-15 to 2027-06-15 on the sponsor's lead Phase 3 GLP-1 obesity program. Registry "Last Update Posted" date is 2026-05-30.
Why it matters. A 6-month primary completion shift on a Phase 3 GLP-1 program affects regulatory submission timeline expectations and competitive positioning relative to adjacent sponsor programs targeting similar 2027 read-outs.
Who may care. Sponsor competitors with overlapping programs, sell-side analysts modeling submission timelines, BD teams evaluating partnership windows, market-access analysts forecasting payer-coverage timing.
Evidence. Direct registry record (link in Evidence Room). No related FDA safety communication. No related sponsor 8-K filing at the time of brief generation.
What changed. Open Targets reports a statistically filtered adverse-event association for the GLP-1R target, sourced from health-professional FAERS reports and scored by likelihood-ratio test at the target level (EMBL-EBI methodology).
Why it matters. Target-level pharmacovigilance evidence — filtered for professional reporters and significance-tested — is more defensible than raw spontaneous-report volumes for class-level surveillance.
Who may care. Pharmacovigilance teams doing public-data triangulation, payers monitoring class adoption, market-access researchers.
Evidence Room — sample record
Every card on Clinical Trial Signal traces back to a primary public record. The Evidence Room exposes the full chain: source, source URL, source timestamp, ingestion timestamp, previous value, new value, the normalized signal we surfaced, and the caveat that constrains how it should be read.